ストックスクリーナーアプリを入手
175.06
1.54%
-2.73
前日終値:
$177.79
開ける：
$177.79
24時間の取引高:
9,803
Relative Volume:
0.04
時価総額：
$6.57B
収益：
-
当期純損益:
$-62.39M
株価収益率:
-91.19
EPS:
-1.9198
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-7.15%
1か月 パフォーマンス:
-1.83%
6か月 パフォーマンス:
+166.29%
1年 パフォーマンス:
+190.03%
1日の値動き範囲:
$173.19
$178.93
1週間の範囲:
$167.59
$192.28
52週間の値動き範囲:
$49.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
175.06 | 6.67B | 0 | -62.39M | 0 | -1.9198 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.26 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.25 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.48 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.00 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.28 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-26 | 開始されました | BofA Securities | Buy |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-02 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 開始されました | Mizuho | Neutral |
| 2023-12-14 | 開始されました | Maxim Group | Buy |
| 2023-07-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 開始されました | SVB Securities | Outperform |
| 2022-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-01 | 開始されました | The Benchmark Company | Buy |
すべてを表示
Belite Bio Inc Adr (BLTE) 最新ニュース
H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria
Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com Nigeria
Belite Bio Q4 Earnings Call Highlights - Defense World
Belite Bio (NASDAQ:BLTE) Given New $266.00 Price Target at Cantor Fitzgerald - Defense World
Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright - MarketBeat
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Price Target Raised to $201.00 - MarketBeat
Belite Bio stock price target raised to $217 by Benchmark on trial data - Investing.com
Belite Bio (NASDAQ:BLTE) Price Target Raised to $266.00 at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook - Investing.com
Earnings call transcript: Belite Bio beats Q4 2025 EPS expectations, stock dips slightly - Investing.com India
Belite Bio (NASDAQ:BLTE) Shares Down 8.6%What's Next? - MarketBeat
Belite Bio to Participate in the Leerink Global Healthcare Conference - wjfw.com
Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win - TipRanks
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Globe and Mail
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com
Exploring Belite Bio's Earnings Expectations - Sahm
Liquidity Mapping Around (BLTE) Price Events - Stock Traders Daily
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter ... - Caledonian Record
China Universal Asset Management Co. Ltd. Acquires New Position in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
Belite Bio (NASDAQ:BLTE) Shares Gap UpStill a Buy? - MarketBeat
Belite Bio, Inc (BLTE) Stock Report: Analyst Ratings Signal Strong Buy with 9.62% Potential Upside - DirectorsTalk Interviews
Darwin Global discloses 8.1% Belite Bio (BLTE) holding in 13G/A - Stock Titan
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Sees Large Growth in Short Interest - Defense World
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Up 49.4% in January - MarketBeat
Why (BLTE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Belite Bio, Inc (BLTE) Stock Analysis: Biotechnology Innovator With 4.98% Potential Upside - DirectorsTalk Interviews
Belite Bio (NASDAQ:BLTE) Shares Down 5.2%Here's Why - MarketBeat
Belite Bio (BLTE) Valuation Check After Completing Enrollment In Pivotal DRAGON II Trial - Sahm
Belite Bio stock hits all-time high at 177.28 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 177.28 USD - Investing.com
Belite Bio (NASDAQ:BLTE) Reaches New 12-Month HighHere's What Happened - MarketBeat
Belite Bio (BLTE) Valuation Check As Phase 3 DRAGON Tinlarebant Data Presentations Approach - Sahm
Understanding Momentum Shifts in (BLTE) - Stock Traders Daily
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target - Investing.com Nigeria
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio completes enrollment in phase 2/3 STGD1 drug trial - Investing.com India
Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease - TipRanks
Belite Bio (NASDAQ:BLTE) Now Covered by Bank of America - Defense World
Belite Bio (NASDAQ:BLTE) Reaches New 1-Year HighStill a Buy? - MarketBeat
Belite Bio Surges on Breakthrough Eye Drug Hopes - TipRanks
Belite Bio stock hits all-time high at $170.35 - Investing.com
Belite Bio stock hits all-time high at $170.35 By Investing.com - Investing.com UK
BofA Securities initiates coverage on Belite Bio stock with Buy rating - Investing.com Canada
BofA Securities initiates coverage on Belite Bio stock with Buy rating By Investing.com - Investing.com South Africa
Stargardt Disease Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics - Barchart.com
Avoiding Lag: Real-Time Signals in (BLTE) Movement - Stock Traders Daily
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Belite Bio Inc Adr (BLTE) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
大文字化:
|
ボリューム (24 時間):